Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9, 2008, Pages 993-1003

  Bredeson, Christopher N ^a   Zhang, Mei Jie ^a,b   Agovi, Manza A ^a,b   Bacigalupo, Andrea ^c   Bahlis, Nizar J ^d   Ballen, Karen ^e   Brown, Christopher ^d   Chaudhry, M Ahsan ^d   Horowitz, Mary M ^a,b   Kurian, Seira ^f   Quinlan, Diana ^d   Muehlenbien, Catherine E ^g   Russell, James A ^d   Savoie, Lynn ^d   Rizzo, J Douglas ^a,b   Stewart, Douglas A ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d Alberta Bone Marrow Transplant Program   (Canada)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Allogeneic transplantation; Antithymocyte globulin; Busulfan

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOLINIC ACID; HLA ANTIGEN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BUSULFAN; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 49649102973     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.06.009     Document Type: Article

References (32)

1. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
2. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
3. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
4. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
5. Sandmaier B.M., Mackinnon S., and Childs R.W. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 13 (2007) 87-97
6. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748
7. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
8. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
9. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 13 (2007) 56-64
10. Jenke A., Freiberg-Richter J., Johne C., et al. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 35 (2005) 627-628
11. Doroshow J.H., and Synold T. Pharmacologic basis for high-dose chemoterapy. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' hematopoietic cell transplantation. 3rd ed. (2004), Blackwell Science Publishers, Malden, MA 130-177
12. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101 (2003) 2043-2048
13. Bacigalupo A., Lamparelli T., Gualandi F., et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 8 (2002) 656-661
14. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
15. Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102 (2003) 470-476
16. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 35 (2005) 1011-1018
17. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
18. Kroger N., Zabelina T., Kruger W., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 29 (2002) 683-689
19. Remberger M., Svahn B.M., Mattsson J., and Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78 (2004) 122-127
20. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 30 (2002) 681-686
21. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
22. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 13 (2007) 299-306
23. Russell J.A., Woodman R.C., Poon M.C., Jones A.R., and Ruether B.A. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 14 (1994) 397-401
24. Sullivan K.M. Graft-versus-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' hematopoietic cell transplantation. 3rd ed. (2004), Blackwell Science Publishers, Malden, MA 635
25. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
26. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
27. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
28. Andersson B.S., De Lima M., Thall P.F., et al. Once daily IV busulfan and Fludarabine (IV Bu-Flu) compares favorably with IV Busulfan and Cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) (in press)
29. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 13 (2007) 814-821
30. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 14 (2008) 220-228
31. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
32. Sobocinski K.A., Thall P.F., Bekele N., et al. Matched pairs analysis of IV vs PO Busulfan as conditioning agent prior to transplantation. Blood 104 (2004) 103a (abstr 349)